The Leading Platform for Long-Read Genomics.
Lucid turns long-read sequencing data into actionable answers covering variant calling, prioritization, interpretation, and reporting in one platform.
Official Compatibility Partner of
the Problem
No Long-Reads Native
Platform Available
Long-reads resolve structural variants, repeat expansions, and methylation that short-reads miss. Yet teams stitch together disconnected tools to interpret them. Most are built for short-read data, and none are designed to capture the full potential of long-reads.
landscape.
variant calls.
non-coding regions.
repeat expansions.
across analysts.
receive molecular diagnosis.
the solution
One platform. Long-read native.
From PacBio HiFi and Oxford Nanopore raw reads to actionable insights. Variant calling, prioritization, interpretation, and reporting — end to end, on one system.
Variant Prioritization
AI variant prioritization with a breakdown of supporting evidence.
Phenotype Match
Link variants with HPO-associated genes for validation.
Coverage Plot
Karyotyping-like inspection of large structural variants.
Differentially Methylated Regions
Check methylation levels vs. control or maternal/paternal alleles.
Validation
What customers say.
Lucid is a spin-off of the Max Planck Institute for Molecular Genetics and Charité Berlin, built on the science of the Mundlos lab, one of Europe's leading rare-disease genomics groups.
Lucid Genomics' cohort analysis tool has been a game changer for our research. It’s intuitive yet powerful, allowing us to quickly compare patient groups and uncover key insights. The platform has streamlined our workflow and enabled faster, data-driven decisions.
Dr. Felix Boschann,
Medical Geneticist, Charité
Lucid cracked 30-year-old unsolved cases — revealing hidden variants and redefining how we see the genome. Simply one of the best tools to unlock the Dark Genome.
Prof. Pawel Stankiewicz,
M.D., Department of Molecular & Human Genetics at Baylor College of Medicine
Lucid integrates AI-driven algorithms allowing our team to quickly identify genetic variants and actionable insights with incredible precision. The intuitive interface and seamless collaboration tools have transformed how we analyze and share insights across teams.
Dr. Marco Saverese,
Principal Investigator, Folkhalsan Research Center
Our Trusted Partners & Collaborators
FIND YOUR SOLUTION
Cut through the noise.
Get to the answer.
Whether you're making diagnostic decisions or pushing the boundaries of discovery, Lucid meets you where the data gets complex.
Frequently Asked Questions
Is my data secure and GDPR-compliant?
Yes. Lucid runs on a GDPR-compliant AWS server in Frankfurt and adheres to the highest data privacy and security standards.
Is Lucid IVDR-certified?
We are currently preparing our IVDR submission and working closely with the relevant regulatory bodies throughout the process.
Can CLIA labs use Lucid?
Yes. Lucid supports your validation study to bring the platform onto your LDT (laboratory-developed test) program.
Do you support on-premise deployment?
Yes, on-premise deployment is possible. The specific requirements are discussed directly with our technical team to fit your infrastructure.
Does Lucid support long-read whole genome sequencing?
Yes. Lucid is purpose-built for long-read WGS analysis, covering SNVs, structural variants, repeat expansions, methylation, non-coding variants, and HPO-based prioritization.
Does Lucid support short-read genome sequencing?
Yes. Lucid supports short-read sequencing in addition to long-read WGS — and you can run mixed family analyses that combine short- and long-read data within the same case.
How do I get started?
We begin with a short intro call to understand your priorities, including a tailored demo and Q&A. From there, we offer a free trial where you can test the platform using public samples or your own in-house samples. Once you've seen it in action, we plan Phase 2: rolling Lucid into your workflow.